{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T01:06:29Z","timestamp":1778288789437,"version":"3.51.4"},"reference-count":42,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T00:00:00Z","timestamp":1764892800000},"content-version":"vor","delay-in-days":1038,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2023,2,23]],"date-time":"2023-02-23T00:00:00Z","timestamp":1677110400000},"content-version":"vor","delay-in-days":22,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,2,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>To compare the cost-effectiveness of immediate and 12-month delayed initiation of dapagliflozin treatment in patients with a history of hospitalization for heart failure (HHF) from the UK, Canadian, German, and Spanish healthcare perspectives.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>A cost-utility analysis was conducted using a decision-analytic Markov model with health states defined by Kansas City Cardiomyopathy Questionnaire scores, type 2 diabetes mellitus status and incidence of heart failure (HF) events. Patient-level data for patients with prior HHF from the Dapagliflozin And Prevention of Adverse-outcomes in Heart Failure (DAPA-HF) trial were used to inform the model inputs on clinical events and utility values. Healthcare costs were sourced from the relevant national reference databases and the published literature. Compared to standard therapy, immediate initiation of dapagliflozin decreased HHF (187 events), urgent HF visits (32 events) and cardiovascular mortality (18 events). Standard therapy was associated with lifetime costs of \u00a313\u2009224 and 4.02 quality-adjusted life years (QALYs). Twelve-month delayed initiation of dapagliflozin was associated with total discounted lifetime costs and QALYs of \u00a316\u2009660 and 4.61, respectively, compared to \u00a316\u2009912 and 4.66, respectively, for immediate initiation. Compared to standard therapy, immediate and 12-month delayed initiation of dapagliflozin yielded an incremental cost-effectiveness ratio (ICER) of \u00a35779 and \u00a35821, respectively. Compared to 12-month delayed initiation, immediate initiation of dapagliflozin had an ICER of \u00a35263. Results were similar from the Canadian, German, and Spanish healthcare perspectives.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Both immediate and 12-month delayed initiation of dapagliflozin are cost-effective. However, immediate initiation provides greater clinical benefits, with almost 10% additional QALYs gain, compared to 12-month delayed initiation of dapagliflozin and should be considered standard of care.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/ejhf.2777","type":"journal-article","created":{"date-parts":[[2023,1,16]],"date-time":"2023-01-16T04:00:18Z","timestamp":1673841618000},"page":"238-247","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Cost-Effectiveness of Immediate Initiation of Dapagliflozin in Patients with a History of Heart Failure"],"prefix":"10.1093","volume":"25","author":[{"given":"Robert J.H.","family":"Miller","sequence":"first","affiliation":[{"name":"Department of Cardiac Sciences, Libin Cardiovascular Institute and Cumming School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Derek S.","family":"Chew","sequence":"additional","affiliation":[{"name":"Department of Cardiac Sciences, Libin Cardiovascular Institute and Cumming School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lei","family":"Qin","sequence":"additional","affiliation":[{"name":"Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca , Gaithersburg, MD ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nowell M.","family":"Fine","sequence":"additional","affiliation":[{"name":"Department of Cardiac Sciences, Libin Cardiovascular Institute and Cumming School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jieling","family":"Chen","sequence":"additional","affiliation":[{"name":"Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca , Gaithersburg, MD ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John J.V.","family":"McMurray","sequence":"additional","affiliation":[{"name":"British Heart Foundation Cardiovascular Research Centre, University of Glasgow , Glasgow ,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan G.","family":"Howlett","sequence":"additional","affiliation":[{"name":"Department of Cardiac Sciences, Libin Cardiovascular Institute and Cumming School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Phil","family":"McEwan","sequence":"additional","affiliation":[{"name":"Health Economics and Outcomes Research Ltd , Cardiff ,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2023,2,23]]},"reference":[{"key":"2026010913083318900_ejhf2777-bib-0001","doi-asserted-by":"crossref","first-page":"7","DOI":"10.15420\/cfr.2016:25:2","article-title":"Global public health burden of heart failure","volume":"3","author":"Savarese","year":"2017","journal-title":"Card Fail Rev"},{"key":"2026010913083318900_ejhf2777-bib-0002","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1016\/j.jacc.2013.11.053","article-title":"The global health and economic burden of hospitalizations for heart failure: lessons learned from hospitalized heart failure registries","volume":"63","author":"Ambrosy","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"2026010913083318900_ejhf2777-bib-0003","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1161\/CIRCULATIONAHA.112.125435","article-title":"Rehospitalization for heart failure: predict or prevent?","volume":"126","author":"Desai","year":"2012","journal-title":"Circulation"},{"key":"2026010913083318900_ejhf2777-bib-0004","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N Engl J Med"},{"key":"2026010913083318900_ejhf2777-bib-0005","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1253\/circj.CJ-18-1087","article-title":"Prognostic impact of previous hospitalization in acute heart failure patients","volume":"83","author":"Akita","year":"2019","journal-title":"Circ J"},{"key":"2026010913083318900_ejhf2777-bib-0006","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1001\/jamacardio.2021.1437","article-title":"Cost-effectiveness of dapagliflozin for treatment of patients with heart failure with reduced ejection fraction","volume":"6","author":"Parizo","year":"2021","journal-title":"JAMA Cardiol"},{"key":"2026010913083318900_ejhf2777-bib-0007","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1002\/ejhf.1978","article-title":"Cost-effectiveness of dapagliflozin as a treatment for heart failure with reduced ejection fraction: a multinational health-economic analysis of DAPA-HF","volume":"22","author":"McEwan","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2026010913083318900_ejhf2777-bib-0008","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1001\/jamacardio.2020.7585","article-title":"Time to clinical benefit of dapagliflozin and significance of prior heart failure hospitalization in patients with heart failure with reduced ejection fraction","volume":"6","author":"Berg","year":"2021","journal-title":"JAMA Cardiol"},{"key":"2026010913083318900_ejhf2777-bib-0009","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.1016\/j.jacc.2019.02.015","article-title":"Titration of medical therapy for heart failure with reduced ejection fraction","volume":"73","author":"Greene","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"2026010913083318900_ejhf2777-bib-0010","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1002\/ejhf.1432","article-title":"A trial to evaluate the effect of the sodium-glucose co-transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA-HF)","volume":"21","author":"McMurray","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"2026010913083318900_ejhf2777-bib-0011","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.cjco.2020.05.009","article-title":"Cost-effectiveness of earlier transition to angiotensin receptor neprilysin inhibitor in patients with heart failure and reduced ejection fraction","volume":"2","author":"Grant","year":"2020","journal-title":"CJC Open"},{"key":"2026010913083318900_ejhf2777-bib-0012","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/s40273-018-0755-x","article-title":"Evaluating cost-effectiveness models for pharmacologic interventions in adults with heart failure: a systematic literature review","volume":"37","author":"Di Tanna","year":"2019","journal-title":"Pharmacoeconomics"},{"key":"2026010913083318900_ejhf2777-bib-0013","volume-title":"Ivabradine for treating chronic heart failure. Technology appraisal guidance [TA267]. 28 November 2012","author":"National Institute for Health and Care Excellence"},{"key":"2026010913083318900_ejhf2777-bib-0014","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1007\/s40273-018-0672-z","article-title":"Discounting in economic evaluations","volume":"36","author":"Attema","year":"2018","journal-title":"Pharmacoeconomics"},{"key":"2026010913083318900_ejhf2777-bib-0015","volume-title":"Guidelines for the Economic Evaluation of Health Technologies: Canada 4th Edition","author":"Canadian Agency for Drugs and Technology in Health"},{"key":"2026010913083318900_ejhf2777-bib-0016","doi-asserted-by":"crossref","first-page":"2364","DOI":"10.1111\/dom.14162","article-title":"Assessing the cost-effectiveness of sodium-glucose cotransporter-2 inhibitors in type 2 diabetes mellitus: a comprehensive economic evaluation using clinical trial and real-world evidence","volume":"22","author":"McEwan","year":"2020","journal-title":"Diabetes Obes Metab"},{"key":"2026010913083318900_ejhf2777-bib-0017","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.hlc.2018.01.011","article-title":"Cost-effectiveness of ivabradine in the treatment of chronic heart failure","volume":"28","author":"Adena","year":"2019","journal-title":"Heart Lung Circ"},{"key":"2026010913083318900_ejhf2777-bib-0018","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1017\/S0266462313000123","article-title":"Cost-effectiveness analysis of cardiac resynchronization therapy in patients with NYHA I and NYHA II heart failure in Spain","volume":"29","author":"Almenar","year":"2013","journal-title":"Int J Technol Assess Health Care"},{"key":"2026010913083318900_ejhf2777-bib-0019","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1136\/heartjnl-2016-310661","article-title":"Cost-effectiveness of sacubitril\/valsartan in the treatment of heart failure with reduced ejection fraction","volume":"104","author":"McMurray","year":"2018","journal-title":"Heart"},{"key":"2026010913083318900_ejhf2777-bib-0020","volume-title":"National life tables: UK","author":"Office for National Statistics"},{"key":"2026010913083318900_ejhf2777-bib-0021","volume-title":"Life Tables, Canada, Provinces and Territories 1980\/1982 to 2017\/2019","author":"Statistics Canada"},{"key":"2026010913083318900_ejhf2777-bib-0022","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes","volume":"380","author":"Wiviott","year":"2019","journal-title":"N Engl J Med"},{"key":"2026010913083318900_ejhf2777-bib-0023","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/j.jval.2012.02.008","article-title":"Interim scoring for the EQ-5D-5L: mapping the EQ-5D-5L to EQ-5D-3L value sets","volume":"15","author":"van Hout","year":"2012","journal-title":"Value Health"},{"key":"2026010913083318900_ejhf2777-bib-0024","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1097\/00005650-199711000-00002","article-title":"Modeling valuations for EuroQol health states","volume":"35","author":"Dolan","year":"1997","journal-title":"Med Care"},{"key":"2026010913083318900_ejhf2777-bib-0025","first-page":"49","article-title":"Evaluation of suspected urinary tract infection in ambulatory women: a cost-utility analysis of office-based strategies","volume":"44","author":"Barry","year":"1997","journal-title":"J Fam Pract"},{"key":"2026010913083318900_ejhf2777-bib-0026","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.jval.2014.03.003","article-title":"Review of utility values for economic modeling in type 2 diabetes","volume":"17","author":"Beaudet","year":"2014","journal-title":"Value Health"},{"key":"2026010913083318900_ejhf2777-bib-0027","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1177\/027298902400448902","article-title":"Estimating utility values for health states of type 2 diabetic patients using the EQ-5D (UKPDS 62)","volume":"22","author":"Clarke","year":"2002","journal-title":"Med Decis Making"},{"key":"2026010913083318900_ejhf2777-bib-0028","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1185\/030079906X115757","article-title":"Multivariate models of health-related utility and the fear of hypoglycaemia in people with diabetes","volume":"22","author":"Currie","year":"2006","journal-title":"Curr Med Res Opin"},{"key":"2026010913083318900_ejhf2777-bib-0029","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1177\/0272989X16658660","article-title":"The impact of diabetes-related complications on preference-based measures of health-related quality of life in adults with type I diabetes","volume":"36","author":"Peasgood","year":"2016","journal-title":"Med Decis Making"},{"key":"2026010913083318900_ejhf2777-bib-0030","volume-title":"Patient Cost Estimator","author":"Canadian Institute for Health Information"},{"key":"2026010913083318900_ejhf2777-bib-0031","volume-title":"Interactive Health Data Application","author":"Government of Alberta"},{"key":"2026010913083318900_ejhf2777-bib-0032","volume-title":"Monthly Index of Medical Specialities"},{"key":"2026010913083318900_ejhf2777-bib-0033","volume-title":"Alberta Drug Benefit List","year":"2019"},{"key":"2026010913083318900_ejhf2777-bib-0034","volume-title":"Medicamentos","author":"Vademecum"},{"key":"2026010913083318900_ejhf2777-bib-0035","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1093\/eurheartj\/ehx026","article-title":"Determinants and clinical outcome of uptitration of ACE-inhibitors and beta-blockers in patients with heart failure: a prospective European study","volume":"38","author":"Ouwerkerk","year":"2017","journal-title":"Eur Heart J"},{"key":"2026010913083318900_ejhf2777-bib-0036","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0140-6736(20)30748-0","article-title":"Estimating lifetime benefits of comprehensive disease-modifying pharmacological therapies in patients with heart failure with reduced ejection fraction","volume":"396","author":"Vaduganathan","year":"2020","journal-title":"Lancet"},{"key":"2026010913083318900_ejhf2777-bib-0037","first-page":"632","article-title":"A novel approach to medical management of heart failure with reduced ejection fraction","volume":"37","author":"Miller","year":"2021","journal-title":"Can J Cardiol"},{"key":"2026010913083318900_ejhf2777-bib-0038","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1001\/jama.2020.1012","article-title":"Changes in list prices, net prices, and discounts for branded drugs in the US, 2007-2018","volume":"323","author":"Hernandez","year":"2020","journal-title":"JAMA"},{"key":"2026010913083318900_ejhf2777-bib-0039","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1002\/ejhf.1713","article-title":"Randomized, double-blind, placebo-controlled, multicentre pilot study on the effects of empagliflozin on clinical outcomes in patients with acute decompensated heart failure (EMPA-RESPONSE-AHF)","volume":"22","author":"Damman","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2026010913083318900_ejhf2777-bib-0040","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2030183","article-title":"Sotagliflozin in patients with diabetes and recent worsening heart failure","volume":"384","author":"Bhatt","year":"2021","journal-title":"N Engl J Med"},{"key":"2026010913083318900_ejhf2777-bib-0041","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1038\/s41591-021-01659-1","article-title":"The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial","volume":"28","author":"Voors","year":"2022","journal-title":"Nat Med"},{"key":"2026010913083318900_ejhf2777-bib-0042","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1001\/jamacardio.2020.2822","article-title":"Cost-effectiveness of sacubitril-valsartan in hospitalized patients who have heart failure with reduced ejection fraction","volume":"5","author":"Gaziano","year":"2020","journal-title":"JAMA Cardiol"}],"container-title":["European Journal of Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ejhf.2777","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/ejhf.2777","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/eurjhf\/article-pdf\/25\/2\/238\/65562186\/eurjhf_25_2_238.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurjhf\/article-pdf\/25\/2\/238\/65562186\/eurjhf_25_2_238.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T18:10:32Z","timestamp":1767982232000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurjhf\/article\/25\/2\/238\/8341736"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,1]]},"references-count":42,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2023,2,23]]},"published-print":{"date-parts":[[2023,2,1]]}},"URL":"https:\/\/doi.org\/10.1002\/ejhf.2777","relation":{},"ISSN":["1388-9842","1879-0844"],"issn-type":[{"value":"1388-9842","type":"print"},{"value":"1879-0844","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,2]]},"published":{"date-parts":[[2023,2,1]]},"assertion":[{"value":"2022-03-24","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-01-12","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-02-23","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}